|
|||||
|
|
Phase 1 dose‐escalating study to evaluate the safety,pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L) |
|
| Authors: | D. Parsons‐Rich F. Hua G. Li C. Kantaridis D. D. Pittman S. Arkin |
| Affiliation: | 1. PharmaTherapeutics Clinical Research, Pfizer Inc., Cambridge, MA, USA;2. PharmaTherapeutics Clinical Research, Pfizer Inc., Collegeville, PA, USA;3. Pfizer Clinical Research Unit, Pfizer Inc., Brussels, Belgium;4. Rare Disease Research, Pfizer Inc., Cambridge, MA, USA |
| Abstract: | |
| Keywords: | activated partial thromboplastin time blood coagulation factor clinical trial hematologic agents hemorrhagic disorders PF‐05230907 |